Nuvalent, Inc.
NASDAQ:NUVLBiotechnology
-$0.03 today
- Market cap
- $9.13B
- Beta
- 1.15
- P/E (TTM)
- -21.6
- EPS (TTM)
- -$5.72
Volume 0.00M
Average 1.91M
NUVL Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Nuvalent, Inc.NASDAQ: NUVL
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables turns negative
Q1 FY2026 accounts payables was -$7.69M, compared with $20.94M a year earlier. Trailing-twelve-month accounts payables was -$4.03M. Over 3 fiscal years it compounded at +80.1% a year.
Context
- Accounts payables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts payables holds near -$7.69M or moves back toward the trailing-twelve-month quarterly average of -$1.01M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 24.6M USD
- Year-over-year change
- +707.5%
- 4-year CAGR
- +96.8%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.6M | +707.5% |
| FY2024 | 2024-12-31 | (4.05M) | -286.7% |
| FY2023 | 2023-12-31 | 2.17M | -48.5% |
| FY2022 | 2022-12-31 | 4.21M | +156.7% |
| FY2021 | 2021-12-31 | 1.64M | — |
Accounts Payables vs competitors
How NUVL compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -131.6% is the 8th highest of 9, against a peer median of +98.1%.
- Over three fiscal years its annual growth of +80.1% compares with a peer median of +90.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $70.56M USD | +253.1% | +90.1% | — | |
| LTM Sep 2026 | $24.96M USD | -30.3% | +142.1% | 8.9% | |
| LTM Sep 2026 | $20.17M USD | -130.7% | — | 0.4% | |
| LTM Sep 2026 | $14.67M USD | +133.3% | -27.7% | 3.3% | |
| LTM Jun 2026 | $12.66M USD | -141.8% | — | 1.6% | |
| LTM Jun 2026 | $7.84M USD | +96.1% | -16.2% | 11.0% | |
| LTM Mar 2026 | $4.03M USD | -131.6% | +80.1% | — | |
| LTM Sep 2026 | $2.29M USD | +190.9% | +105.6% | 9.1% | |
| FY2025 | €0 EUR | +100.0% | — | — | |
| Peer median (excluding NUVL) | — | +98.1% | +90.1% | 6.1% | |
Competitors are the stored peer set for NUVL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (46.34M) | (81.85M) | (126.22M) | (260.76M) | (425.38M) |
| Depreciation & Amortization | 215K | (373K) | 0 | 0 | 0 |
| Deferred Income Tax | (215K) | (5.74M) | 0 | 0 | 0 |
| Stock-Based Compensation | 3.55M | 10.33M | 25.56M | 60.58M | 86.5M |
| Change in Working Capital | 1.94M | 6.93M | 11.03M | 11.84M | 19.21M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.64M | 4.21M | 2.17M | (4.05M) | 24.6M |
| Other Working Capital | 300K | 2.72M | 8.86M | 15.89M | (5.39M) |
| Other Non-Cash Items | 846K | 5.74M | (10.11M) | 3.27M | 44.46M |
| Operating Cash Flow | (40M) | (64.97M) | (99.74M) | (185.06M) | (275.21M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (221.04M) | (212.92M) | (459.49M) | (1.02B) | (1.06B) |
| Sales of Investments | 1.02M | 202.25M | 315.96M | 451.45M | 933.69M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (220.03M) | (10.67M) | (143.53M) | (573.51M) | (124.08M) |
| Debt Repayment | 284K | 0 | 0 | 0 | 0 |
| Common Stock Issued | 177.27M | 248.63M | 324.3M | 569.99M | 515.34M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.98M) | 286K | 12.55M | (1.11M) | 0 |
| Financing Cash Flow | 318.22M | 248.92M | 336.85M | 568.88M | 515.34M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 58.19M | 173.28M | 93.58M | (189.7M) | 116.05M |
| Free Cash Flow | (40M) | (64.97M) | (99.74M) | (185.06M) | (275.21M) |
Nuvalent, Inc.
NASDAQ:NUVL
Intrinsic Alpha fair value
Locked
Current Price
$123.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.